文献速递神经肿瘤

内镜与显微镜经蝶窦垂体腺瘤手术的成本效果分析

Cost-Effectiveness of Endoscopic Versus Microscopic Transsphenoidal Surgery for Pituitary Adenoma.
PubMed 文献 · World Neurosurg · 2017-11-20

本研究构建马尔可夫模型,从单一支付方医疗视角比较内镜经蝶窦手术(ETPS)与显微镜经蝶窦手术(MTPS)治疗垂体腺瘤的成本效果,数据来自已发表结局研究,成本基于Medicare报销费率,基础病例随访2年。结果显示ETPS平均节省143美元并多获得0.014个质量调整生命年(QALY),增量成本效果比(ICER)为每QALY -10214美元,提示经济优势;模型至10年时QALY获益增至0.105。

要点

  • ETPS较MTPS平均节省143美元,多获得0.014个QALY(2年随访)。
  • ICER为每QALY -10214美元,低于常用50000美元/QALY阈值,提示ETPS具成本效果。
  • 模型至10年时QALY获益增至0.105,提示ETPS随时间推移更有利。

核心结论

  • ETPS与MTPS相比似乎具成本效果,因ICER低于常用50000美元/QALY基准。
  • 模型局限与假设影响结论的普适性;持续改善ETPS相关鼻科并发症似可进一步增加边际成本节约与QALY获益。
  • 需进一步开展使用前瞻性数据的ETPS成本效果研究。

研究设计与样本

  • 构建马尔可夫模型,从单一支付方医疗视角对ETPS与MTPS进行成本效用分析。
  • 数据来自既往已发表结局研究,成本基于Medicare报销费率,并考虑并发症、住院时长和手术时间等协变量。
  • 基础病例采用2年随访期,并进行单变量和多变量敏感性分析。

主要发现

  • 2年内ETPS平均较MTPS节省143美元,并多获得0.014个QALY。
  • ICER为每QALY -10214美元,提示经济优势。
  • 模型至10年时QALY获益增至0.105,提示ETPS随时间推移更有利。

关键数值与推荐

  • ICER为每QALY -10214美元,低于常用50000美元/QALY基准。
  • 2年内ETPS较MTPS平均节省143美元,多获得0.014个QALY。
  • 模型至10年时QALY获益为0.105。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 模型局限与假设影响结论的普适性。
  • 需进一步开展使用前瞻性数据的ETPS成本效果研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endoscopic transsphenoidal surgery (ETPS) has become increasingly popular for resection of pituitary tumors, whereas microscopic transsphenoidal surgery (MTPS) also remains a commonly used approach. The economic sustainability of new techniques and technologies is rarely evaluated in the neurosurgical skull base literature. The aim of this study was to determine the cost-effectiveness of ETPS compared with MTPS. METHODS: A Markov model was constructed to conduct a cost-utility analysis of ETPS versus MTPS from a single-payer health care perspective. Data were obtained from previously published outcomes studies. Costs were based on Medicare reimbursement rates, considering covariates such as complications, length of stay, and operative time. The base case adopted a 2-year follow-up period. Univariate and multivariate sensitivity analyses were conducted. RESULTS: On average, ETPS costs $143 less and generates 0.014 quality-adjusted life years (QALYs) compared with MTPS over 2 years. The incremental cost-effectiveness ratio (ICER) is -$10,214 per QALY, suggesting economic dominance. The QALY benefit increased to 0.105 when modeled to 10 years, suggesting that ETPS becomes even more favorable over time. CONCLUSIONS: ETPS appears to be cost-effective when compared with MTPS because the ICER falls below the commonly accepted $50,000 per QALY benchmark. Model limitations and assumptions affect the generalizability of the conclusion; however, ongoing efforts to improve rhinologic morbidity related to ETPS would appear to further augment the marginal cost savings and QALYs gained. Further research on the cost-effectiveness of ETPS using prospective data is warranted.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Ament JD, Yang Z, Khatchadourian V, et al. Cost-Effectiveness of Endoscopic Versus Microscopic Transsphenoidal Surgery for Pituitary Adenoma. World Neurosurg. 2017. PMID: 29158096. doi:10.1016/j.wneu.2017.11.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。